Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/26/26
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of TherapyGlobeNewsWire • 06/11/26
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg ExpansionsSeeking Alpha • 06/09/26
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?Zacks Investment Research • 06/09/26
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases TranscriptSeeking Alpha • 06/08/26
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock FlyingInvestors Business Daily • 06/08/26
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer MarketBenzinga • 06/08/26
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyGlobeNewsWire • 06/08/26
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurologyGlobeNewsWire • 06/08/26
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/22/26
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual MeetingGlobeNewsWire • 05/14/26
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association CongressGlobeNewsWire • 05/12/26
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026GlobeNewsWire • 04/22/26
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptSeeking Alpha • 04/17/26
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?Zacks Investment Research • 04/10/26
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 04/08/26